What is the appropriate nivolumab dose and schedule for recurrent/metastatic head‑and‑neck squamous cell carcinoma?

Nivolumab Dosing for Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

For recurrent or metastatic head and neck squamous cell carcinoma, administer nivolumab 240 mg every 2 weeks or 480 mg every 4 weeks as monotherapy. 1

FDA-Approved Dosing Regimens

The FDA label explicitly states for recurrent or metastatic squamous cell carcinoma of the head and neck 1:

• 240 mg IV every 2 weeks, OR
• 480 mg IV every 4 weeks

Both regimens are equivalent in efficacy and safety based on pharmacokinetic modeling showing no clinically significant exposure-response differences across approved dosing schedules 1.

Evidence Supporting This Recommendation

Pivotal Trial Data

The landmark CheckMate 141 trial, which established nivolumab as standard of care, used 3 mg/kg every 2 weeks (equivalent to approximately 240 mg for a 80 kg patient) 2. This regimen demonstrated:

• Median OS: 7.5 months vs 5.1 months with chemotherapy (HR 0.70, p=0.01)
• 1-year survival: 36.0% vs 16.6%
• Grade 3-4 treatment-related adverse events: 13.1% vs 35.1%
• Maintained quality of life vs deterioration with chemotherapy 3

Guideline Endorsement

The 2023 ASCO guideline supports anti-PD-1 inhibitors for recurrent/metastatic HNSCC after platinum failure, citing phase II studies using nivolumab 240 mg every 2 weeks with 20.8% objective response rates 4. While evidence quality is rated as low to moderate, the clinical benefit with lower toxicity compared to chemotherapy supports this approach.

Practical Dosing Considerations

Choose the 2-week schedule (240 mg) when:

• Closer monitoring is desired for immune-related adverse events
• Patient preference for more frequent clinic visits
• Combining with other therapies requiring biweekly administration

Choose the 4-week schedule (480 mg) when:

• Reducing treatment burden and clinic visits
• Patient lives far from treatment center
• Stable disease with established tolerability

Common Pitfalls to Avoid

1. Do not use weight-based dosing (3 mg/kg) - The flat dosing regimens (240 mg or 480 mg) are now standard and eliminate dosing errors 1

2. Do not delay treatment for PD-L1 testing - While PD-L1 CPS ≥1 predicts better pembrolizumab response, nivolumab shows activity regardless of PD-L1 status 4

3. Prior cetuximab exposure does not preclude nivolumab - CheckMate 141 subgroup analysis showed benefit regardless of prior cetuximab use, though the hazard ratio was more favorable in cetuximab-naive patients (HR 0.52 vs 0.84) 5

4. Continue until progression or unacceptable toxicity - Unlike chemotherapy with fixed cycle limits, immunotherapy continues as long as clinical benefit persists 1

Infusion Details

Administer as IV infusion over 30 minutes (60 minutes is also acceptable but not required) 1. The predicted exposure with 30-minute infusion is comparable to 60-minute infusion based on pharmacokinetic modeling 1.

Monitoring Requirements

Baseline and periodic monitoring should include:

• Liver enzymes (AST/ALT, bilirubin)
• Creatinine/eGFR
• Thyroid function (TSH, free T4)

This allows early detection of immune-mediated adverse events, which occur in approximately 13% of patients at grade 3-4 severity 2.